137 related articles for article (PubMed ID: 32011530)
1. Predictors of Recurrence and Survival in Patients With Surgically Resected Pancreatic Neuroendocrine Tumors.
Rosenblum RE; Harris CK; Baeg KJ; Starr JA; Brais LK; Stashek KM; Ward SC; Katona BW; Clancy TE; Wisnivesky JP; Kulke MH; Metz DC; Kim MK; Chan JA
Pancreas; 2020 Feb; 49(2):249-254. PubMed ID: 32011530
[TBL] [Abstract][Full Text] [Related]
2. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications.
Strosberg JR; Cheema A; Weber JM; Ghayouri M; Han G; Hodul PJ; Kvols LK
Ann Surg; 2012 Aug; 256(2):321-5. PubMed ID: 22415420
[TBL] [Abstract][Full Text] [Related]
3. A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients.
Zaidi MY; Lopez-Aguiar AG; Switchenko JM; Lipscomb J; Andreasi V; Partelli S; Gamboa AC; Lee RM; Poultsides GA; Dillhoff M; Rocha FG; Idrees K; Cho CS; Weber SM; Fields RC; Staley CA; Falconi M; Maithel SK
Ann Surg; 2019 Sep; 270(3):422-433. PubMed ID: 31283562
[TBL] [Abstract][Full Text] [Related]
4. The Postoperative Occurrence or Worsening of Diabetes Mellitus May Increase the Risk of Recurrence in Resected Pancreatic Neuroendocrine Tumors.
de Mestier L; Védie AL; Faron M; Cros J; Rebours V; Hentic O; Do Cao C; Bardet P; Lévy P; Sauvanet A; Ruszniewski P; Hammel P
Neuroendocrinology; 2020; 110(11-12):967-976. PubMed ID: 31791037
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for short recurrence-free survival after resection of pancreatic neuroendocrine tumor (PanNET) liver metastases: which patients should undergo resection?
Masui T; Nagai K; Anazawa T; Kasai Y; Sato A; Nakano K; Uchida Y; Yogo A; Kawaguchi Y; Takaori K; Uemoto S
Scand J Gastroenterol; 2020 Apr; 55(4):479-484. PubMed ID: 32223573
[No Abstract] [Full Text] [Related]
6. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
[TBL] [Abstract][Full Text] [Related]
7. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
[TBL] [Abstract][Full Text] [Related]
8. Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database.
Chan H; Zhang L; Choti MA; Kulke M; Yao JC; Nakakura EK; Bloomston M; Benson AB; Shah MH; Strosberg JR; Bergsland EK; Van Loon K
Pancreas; 2021 Apr; 50(4):506-512. PubMed ID: 33939661
[TBL] [Abstract][Full Text] [Related]
9. Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor.
Gao H; Liu L; Wang W; Xu H; Jin K; Wu C; Qi Z; Zhang S; Liu C; Xu J; Ni Q; Yu X
Cancer Lett; 2018 Jan; 412():188-193. PubMed ID: 29107104
[TBL] [Abstract][Full Text] [Related]
10. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
[TBL] [Abstract][Full Text] [Related]
11. A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors.
Sho S; Court CM; Winograd P; Toste PA; Pisegna JR; Lewis M; Donahue TR; Hines OJ; Reber HA; Dawson DW; Tomlinson JS
J Gastrointest Surg; 2019 Jul; 23(7):1392-1400. PubMed ID: 30353489
[TBL] [Abstract][Full Text] [Related]
12. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors.
Titan AL; Norton JA; Fisher AT; Foster DS; Harris EJ; Worhunsky DJ; Worth PJ; Dua MM; Visser BC; Poultsides GA; Longaker MT; Jensen RT
JAMA Netw Open; 2020 Nov; 3(11):e2024318. PubMed ID: 33146734
[TBL] [Abstract][Full Text] [Related]
14. Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs).
Cai L; Michelakos T; Deshpande V; Arora KS; Yamada T; Ting DT; Taylor MS; Castillo CF; Warshaw AL; Lillemoe KD; Ferrone S; Ferrone CR
Clin Cancer Res; 2019 Apr; 25(8):2644-2655. PubMed ID: 30670493
[TBL] [Abstract][Full Text] [Related]
15. Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors.
Pulvirenti A; Javed AA; Landoni L; Jamieson NB; Chou JF; Miotto M; He J; Gonen M; Pea A; Tang LH; Nessi C; Cingarlini S; D'Angelica MI; Gill AJ; Kingham TP; Scarpa A; Weiss MJ; Balachandran VP; Samra JS; Cameron JL; Jarnagin WR; Salvia R; Wolfgang CL; Allen PJ; Bassiy C
Ann Surg; 2021 Dec; 274(6):1051-1057. PubMed ID: 31567347
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study.
Zhang P; Li YL; Qiu XD; Luo J; Shi YF; Sun YL; Su F; Qi ZR; Tan HY
World J Surg Oncol; 2019 Apr; 17(1):66. PubMed ID: 30975157
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral Fibrosis and Tumor Growth Pattern as Prognostic Factors in Optimally Resected Pancreatic Neuroendocrine Neoplasms: An Analysis of 168 Cases.
Chatterjee D; Trikalinos NA; Williams GA; Liu J; Hawkins WG; Hammill C
Pancreas; 2020 Feb; 49(2):255-260. PubMed ID: 32011527
[TBL] [Abstract][Full Text] [Related]
19. Operative resection in early stage pancreatic neuroendocrine tumors in the United States: Are we over- or undertreating patients?
Chivukula SV; Tierney JF; Hertl M; Poirier J; Keutgen XM
Surgery; 2020 Jan; 167(1):180-186. PubMed ID: 31537303
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic and prognostic significance of multiple hormone expression in pancreatic neuroendocrine tumors.
Kim JY; Kim MS; Kim KS; Song KB; Lee SH; Hwang DW; Kim KP; Kim HJ; Yu E; Kim SC; Jang HJ; Hong SM
Am J Surg Pathol; 2015 May; 39(5):592-601. PubMed ID: 25602797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
